Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response

Immunol Res. 2008;41(3):165-74. doi: 10.1007/s12026-008-8019-z.

Abstract

Statins' recently discovered anti-inflammatory effects place them at the forefront of the new therapies for chronic inflammatory and autoimmune diseases. Our recent study demonstrated that simvastatin exerts an independent immunomodulatory effect on the human monocytes and CD4+ cells. In addition to the statin-mediated effect on the monocyte cytokine production, which regulates Th17 cell differentiation, simvastatin directly inhibits IL-17 production in CD4+ cells, which may collectively inhibit the autoimmune response in multiple sclerosis (MS), a central nervous system (CNS) inflammatory demyelinating disease.

Publication types

  • Review

MeSH terms

  • Antigen-Presenting Cells / immunology
  • Antigen-Presenting Cells / metabolism
  • Autoimmunity / immunology
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism
  • Cell Differentiation / immunology
  • Cytokines / immunology
  • Cytokines / metabolism
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Immunologic Factors / pharmacology*
  • Immunologic Factors / therapeutic use
  • Interleukin-17 / immunology*
  • Interleukin-17 / metabolism
  • Membrane Microdomains / immunology
  • Membrane Microdomains / pathology
  • Monocytes / immunology
  • Monocytes / metabolism
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Simvastatin / pharmacology*
  • Simvastatin / therapeutic use
  • Th1 Cells / drug effects*
  • Th1 Cells / immunology
  • Th1 Cells / metabolism
  • Th2 Cells / immunology
  • Th2 Cells / metabolism

Substances

  • Cytokines
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Immunologic Factors
  • Interleukin-17
  • Simvastatin